1. Home
  2. AKRO vs SNDR Comparison

AKRO vs SNDR Comparison

Compare AKRO & SNDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • SNDR
  • Stock Information
  • Founded
  • AKRO 2017
  • SNDR 1935
  • Country
  • AKRO United States
  • SNDR United States
  • Employees
  • AKRO N/A
  • SNDR N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • SNDR Trucking Freight/Courier Services
  • Sector
  • AKRO Health Care
  • SNDR Industrials
  • Exchange
  • AKRO Nasdaq
  • SNDR Nasdaq
  • Market Cap
  • AKRO 3.7B
  • SNDR 4.0B
  • IPO Year
  • AKRO 2019
  • SNDR 2017
  • Fundamental
  • Price
  • AKRO $54.00
  • SNDR $22.63
  • Analyst Decision
  • AKRO Buy
  • SNDR Buy
  • Analyst Count
  • AKRO 10
  • SNDR 14
  • Target Price
  • AKRO $73.56
  • SNDR $26.79
  • AVG Volume (30 Days)
  • AKRO 4.1M
  • SNDR 1.2M
  • Earning Date
  • AKRO 11-07-2025
  • SNDR 10-30-2025
  • Dividend Yield
  • AKRO N/A
  • SNDR 1.67%
  • EPS Growth
  • AKRO N/A
  • SNDR 5.54
  • EPS
  • AKRO N/A
  • SNDR 0.70
  • Revenue
  • AKRO N/A
  • SNDR $5,477,100,000.00
  • Revenue This Year
  • AKRO N/A
  • SNDR $10.25
  • Revenue Next Year
  • AKRO N/A
  • SNDR $4.95
  • P/E Ratio
  • AKRO N/A
  • SNDR $32.43
  • Revenue Growth
  • AKRO N/A
  • SNDR 2.20
  • 52 Week Low
  • AKRO $21.34
  • SNDR $20.59
  • 52 Week High
  • AKRO $58.40
  • SNDR $33.90
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 68.71
  • SNDR 48.48
  • Support Level
  • AKRO $53.40
  • SNDR $22.33
  • Resistance Level
  • AKRO $54.05
  • SNDR $23.17
  • Average True Range (ATR)
  • AKRO 0.26
  • SNDR 0.62
  • MACD
  • AKRO -0.03
  • SNDR 0.04
  • Stochastic Oscillator
  • AKRO 72.46
  • SNDR 38.39

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About SNDR Schneider National Inc.

Schneider National Inc is a provider of surface transportation and logistics solutions in North America. The Company offers truckload, intermodal, and logistics services to a diverse customer base throughout the continental United States, Canada, and Mexico. The company's segments include Truckload; Intermodal; Logistics and other. It generates maximum revenue from the Truckload segment.

Share on Social Networks: